{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:08:09Z","timestamp":1777075689928,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.cbi.2016.07.001","type":"journal-article","created":{"date-parts":[[2016,7,4]],"date-time":"2016-07-04T12:16:35Z","timestamp":1467634595000},"page":"257-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Enantioselective inhibition of Cytochrome P450-mediated drug metabolism by a novel antithrombotic agent, S002-333: Major effect on CYP2B6"],"prefix":"10.1016","volume":"256","author":[{"given":"Manisha","family":"Bhateria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachumallu","family":"Ramakrishna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santosh Kumar","family":"Puttrevu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil K.","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabi Sankar","family":"Bhatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cbi.2016.07.001_bib1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/clpt.2009.98","article-title":"New antithrombotic drugs","volume":"86","author":"Gross","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"issue":"suppl. 6","key":"10.1016\/j.cbi.2016.07.001_bib2","doi-asserted-by":"crossref","first-page":"234S","DOI":"10.1378\/chest.08-0673","article-title":"New antithrombotic drugs: American college of chest physicians evidence-based clinical practice guidelines *","volume":"133","author":"Weitz","year":"2008","journal-title":"CHEST J."},{"key":"10.1016\/j.cbi.2016.07.001_bib3","unstructured":"S. Gaur, Z. Fatima, A. Dixit, Z. Ali, W. Surin, K. Kapoor, K. Bhutani, M. Ansari, M. Dikshit, A. Saxena, 2-Alkyl\/aryl sulphonyl-1, 2, 3, 4-tetrahydro-9h-pyrido (3, 4-b) indole-3-carboxylic acid esters\/amides useful as antithrombotic agents, U.S. Patent Application 11\/842,674, 2007."},{"issue":"9","key":"10.1016\/j.cbi.2016.07.001_bib4","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s00044-010-9422-2","article-title":"Bioanalytical method development and validation for simultaneous estimation of (R)-and (S)-isomers of S002-333: a potent novel anti-thrombotic agent using LC\u2013MS\/MS","volume":"20","author":"Bhatta","year":"2011","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.cbi.2016.07.001_bib5","series-title":"The Impact of Stereochemistry on Drug Development and Use","author":"Aboul-Enein","year":"1997"},{"issue":"18","key":"10.1016\/j.cbi.2016.07.001_bib6","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1001\/jama.281.18.1728","article-title":"The safety of newly approved medicines: do recent market removals mean there is a problem?","volume":"281","author":"Friedman","year":"1999","journal-title":"Jama"},{"issue":"5","key":"10.1016\/j.cbi.2016.07.001_bib7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2133\/dmpk.DMPK-12-RG-014","article-title":"Reliable high-throughput method for inhibition assay of 8 cytochrome P450 isoforms using cocktail of probe substrates and stable isotope-labeled internal standards","volume":"27","author":"Kozakai","year":"2012","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.cbi.2016.07.001_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1365-2125.2001.01313.x","article-title":"Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol","volume":"51","author":"Shin","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.cbi.2016.07.001_bib9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/(SICI)1520-636X(1997)9:3<281::AID-CHIR13>3.0.CO;2-J","article-title":"Stereoselective inhibition of rat brain cyclooxygenase by dexketoprofen","volume":"9","author":"Carabaza","year":"1997","journal-title":"Chirality"},{"issue":"2","key":"10.1016\/j.cbi.2016.07.001_bib10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/chir.10294","article-title":"Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: testosterone and methadone as substrates","volume":"16","author":"Dilmaghanian","year":"2004","journal-title":"Chirality"},{"issue":"4","key":"10.1016\/j.cbi.2016.07.001_bib11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/00498254.2013.831958","article-title":"In\u00a0vitro metabolism of a novel antithrombotic compound, S002-333, and its enantiomers: quantitative cytochrome P450 phenotyping, metabolic profiling and enzyme kinetic studies","volume":"44","author":"Saxena","year":"2014","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.cbi.2016.07.001_bib12","first-page":"23","article-title":"A\u00a0method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in\u00a0vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry","volume":"29","author":"Dierks","year":"2001","journal-title":"Drug Metab. Dispos."},{"issue":"10","key":"10.1016\/j.cbi.2016.07.001_bib13","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/rcm.290","article-title":"High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1","volume":"15","author":"Bu","year":"2001","journal-title":"Rapid Commun. Mass Spectrom."},{"issue":"5","key":"10.1016\/j.cbi.2016.07.001_bib14","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0731-7085(02)00480-6","article-title":"High-throughput inhibition screening of major human cytochrome P450 enzymes using an in\u00a0vitro cocktail and liquid chromatography\u2013tandem mass spectrometry","volume":"30","author":"Testino","year":"2003","journal-title":"J.\u00a0Pharm. Biomed. Analysis"},{"issue":"18","key":"10.1016\/j.cbi.2016.07.001_bib15","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1002\/rcm.2110","article-title":"High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in\u00a0vitro using liquid chromatography\/tandem mass spectrometry","volume":"19","author":"Kim","year":"2005","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.cbi.2016.07.001_bib16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jpba.2014.03.018","article-title":"A\u00a0cocktail approach for assessing the in\u00a0vitro activity of human cytochrome P450s: an overview of current methodologies","volume":"101","author":"Spaggiari","year":"2014","journal-title":"J.\u00a0Pharm. Biomed. Analysis"},{"issue":"7","key":"10.1016\/j.cbi.2016.07.001_bib17","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.31.7.815","article-title":"The conduct of in\u00a0vitro and in\u00a0vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective","volume":"31","author":"Bjornsson","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2016.07.001_bib18","article-title":"Guidance for industry: drug interaction studies: study design, data analysis, and implications for dosing and labeling","author":"US Food and Drug Administration","year":"2006"},{"issue":"1","key":"10.1016\/j.cbi.2016.07.001_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/187231211794455235","article-title":"An in\u00a0vitro, high throughput, seven CYP cocktail inhibition assay for the evaluation of new chemical entities using LC-MS\/MS","volume":"5","author":"Otten","year":"2011","journal-title":"Drug Metab. Lett."},{"issue":"7","key":"10.1016\/j.cbi.2016.07.001_bib20","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1124\/dmd.109.026716","article-title":"The conduct of in\u00a0vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America","volume":"37","author":"Grimm","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.cbi.2016.07.001_bib21","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1208\/s12248-008-9042-7","article-title":"In\u00a0vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug\u2013drug interactions","volume":"10","author":"Fowler","year":"2008","journal-title":"AAPS J."},{"issue":"2","key":"10.1016\/j.cbi.2016.07.001_bib22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","article-title":"Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions","volume":"35","author":"Obach","year":"2007","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.cbi.2016.07.001_bib23","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1046\/j.1365-2125.1997.00591.x","article-title":"Venlafaxine: in\u00a0vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2","volume":"43","author":"Ball","year":"1997","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.cbi.2016.07.001_bib24","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/jama.1993.03500120051025","article-title":"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences","volume":"269","author":"Honig","year":"1993","journal-title":"Jama"},{"issue":"12","key":"10.1016\/j.cbi.2016.07.001_bib25","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jama.1993.03500120088033","article-title":"Understanding consequences of concurrent therapies","volume":"269","author":"Peck","year":"1993","journal-title":"Jama"},{"issue":"10\u201311","key":"10.1016\/j.cbi.2016.07.001_bib26","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1080\/00498250701670945","article-title":"Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment","volume":"37","author":"Venkatakrishnan","year":"2007","journal-title":"Xenobiotica"},{"issue":"3","key":"10.1016\/j.cbi.2016.07.001_bib27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/138920006776359293","article-title":"A\u00a0critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in\u00a0vitro-in\u00a0vivo extrapolation","volume":"7","author":"Ghanbari","year":"2006","journal-title":"Curr. Drug Metab."},{"issue":"2","key":"10.1016\/j.cbi.2016.07.001_bib28","first-page":"70","article-title":"Stereochemistry in drug action","volume":"5","author":"McConathy","year":"2003","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.cbi.2016.07.001_bib29","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1128\/AAC.41.7.1465","article-title":"Stereoselective interaction of the azole antifungal agent SCH39304 with the cytochrome P-450 monooxygenase system isolated from Cryptococcus neoformans","volume":"41","author":"Lamb","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.cbi.2016.07.001_bib30","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17425255.2012.667801","article-title":"In\u00a0vitro-to-in\u00a0vivo predictions of drug\u2013drug interactions involving multiple reversible inhibitors","volume":"8","author":"Lutz","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.cbi.2016.07.001_bib31","series-title":"Drug Development and Drug Interactions: Table\u00a0of Substrates, Inhibitors and Inducers","author":"U. Food, D. Administration","year":"2011"},{"issue":"12","key":"10.1016\/j.cbi.2016.07.001_bib32","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1124\/dmd.30.12.1311","article-title":"Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in\u00a0vitro drug interactions","volume":"30","author":"Yuan","year":"2002","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.cbi.2016.07.001_bib33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/bdd.552","article-title":"In\u00a0vitro LC-MS cocktail assays to simultaneously determine human cytochrome P450 activities","volume":"28","author":"Dixit","year":"2007","journal-title":"Biopharm. Drug Dispos."},{"issue":"1","key":"10.1016\/j.cbi.2016.07.001_bib34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12154-009-0029-3","article-title":"Hill coefficients, dose\u2013response curves and allosteric mechanisms","volume":"3","author":"Prinz","year":"2010","journal-title":"J.\u00a0Chem. Biol."},{"issue":"6","key":"10.1016\/j.cbi.2016.07.001_bib35","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1124\/dmd.32.6.626","article-title":"Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in\u00a0vitro","volume":"32","author":"Turpeinen","year":"2004","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.cbi.2016.07.001_bib36","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1086\/499369","article-title":"Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance","volume":"42","author":"Nolan","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"10.1016\/j.cbi.2016.07.001_bib37","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1124\/dmd.108.020727","article-title":"Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl) cyclobutyl]-3-methylbutyl}-N, N-dimethylamine) metabolites in human liver microsomes","volume":"36","author":"Bae","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"10","key":"10.1016\/j.cbi.2016.07.001_bib38","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S0026-895X(24)12046-9","article-title":"CYP2B6 mediates the in\u00a0vitro hydroxylation of bupropion: potential drug interactions with other antidepressants","volume":"28","author":"Hesse","year":"2000","journal-title":"Drug Metab. Dispos."},{"issue":"7","key":"10.1016\/j.cbi.2016.07.001_bib39","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2174\/138920006778520633","article-title":"The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in\u00a0vitro, in\u00a0vivo and in silico","volume":"7","author":"Turpeinen","year":"2006","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.cbi.2016.07.001_bib40","series-title":"Pharmacology: Principles and Practice","author":"Hacker","year":"2009"},{"issue":"6","key":"10.1016\/j.cbi.2016.07.001_bib41","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1023\/A:1018906614320","article-title":"Inhibition of human CYP3A catalyzed 1\u2032-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine","volume":"11","author":"Wrighton","year":"1994","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.cbi.2016.07.001_bib42","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1359-6446(03)02904-0","article-title":"Trends in the development of chiral drugs","volume":"9","author":"Caner","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.cbi.2016.07.001_bib43","unstructured":"http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm122883.htm)."},{"issue":"1","key":"10.1016\/j.cbi.2016.07.001_bib44","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jpba.2007.02.034","article-title":"Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC\u2013MS\/MS analysis","volume":"44","author":"Yao","year":"2007","journal-title":"J.\u00a0Pharm. Biomed. Analysis"},{"issue":"6","key":"10.1016\/j.cbi.2016.07.001_bib45","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1124\/dmd.32.6.647","article-title":"Validated assays for human cytochrome P450 activities","volume":"32","author":"Walsky","year":"2004","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.cbi.2016.07.001_bib46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejps.2004.10.006","article-title":"Multiple P450 substrates in a single run: rapid and comprehensive in\u00a0vitro interaction assay","volume":"24","author":"Turpeinen","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.cbi.2016.07.001_bib47","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2125.1998.00679.x","article-title":"Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes","volume":"45","author":"Eagling","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.cbi.2016.07.001_bib48","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/004982598239092","article-title":"Effects of propofol on human hepatic microsomal cytochrome P450 activities","volume":"28","author":"McKillop","year":"1998","journal-title":"Xenobiotica"},{"issue":"8","key":"10.1016\/j.cbi.2016.07.001_bib49","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/1099-081X(199911)20:8<385::AID-BDD203>3.0.CO;2-7","article-title":"Inhibition of human cytochrome P450 isoforms in\u00a0vitro by zafirlukast","volume":"20","author":"Shader","year":"1999","journal-title":"Biopharm. Drug Dispos."},{"issue":"9","key":"10.1016\/j.cbi.2016.07.001_bib50","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0090-9556(24)15020-9","article-title":"Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli","volume":"27","author":"McGinnity","year":"1999","journal-title":"Drug Metab. Dispos."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279716302757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279716302757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T13:42:31Z","timestamp":1757857351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279716302757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":50,"alternative-id":["S0009279716302757"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2016.07.001","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enantioselective inhibition of Cytochrome P450-mediated drug metabolism by a novel antithrombotic agent, S002-333: Major effect on CYP2B6","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2016.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}